



# Biotech Daily

Thursday June 19, 2025

*Daily news on ASX-listed biotechnology companies*

## Amplia Up 203% On 2nd AMP945 Pancreatic Cancer Complete Response

### AMPLIA THERAPEUTICS

Amplia was up as much as 202.5 percent on news that its AMP945, or narmafotinib, led to a second confirmed complete response in a pancreatic cancer patient.

On Monday, the company said narmafotinib, or AMP945, with chemotherapy, for pancreatic cancer led to one 'pathological complete response' (BD: Jun 16, 2025).

Today, Amplia said a confirmed complete response was "a formal designation of response where there is a complete disappearance of all tumor lesions that is maintained for more than two months".

The company said a confirmed complete response was "a rare outcome in advanced pancreatic cancer where the disease has spread to other parts of the body".

Last month, Amplia said its 55-patient, phase Ib/IIa 'Accent' trial showed narmafotinib with standard-of-care chemotherapies gemcitabine and Abraxane led to 15 metastatic pancreatic cancer partial responses (BD: May 15, 2025).

At that time, Amplia managing-director Dr Chris Burns told Biotech Daily that 15 partial responses from 55 patients was better than the chemotherapy alone historical average.

Amplia said a previous study had shown the chemotherapies gemcitabine and Abraxane efficacy in advanced pancreatic cancer reported one complete response of 431 patients.

Today, Dr Burns said that a second complete response in the trial was “really wonderful news, particularly given how rare these are observed in advanced pancreatic cancer”.

“Along with the pathological [complete response] announced earlier in the week, this outcome further demonstrates the promising activity narmafotinib, on top of standard-of-care, is showing in pancreatic cancer,” Dr Burns said.

Amplia climbed as much as 16.4 cents or 202.5 percent to 24.5 cents, before closing up 15.4 cents or 190.1 percent at 23.5 cents with 88.1 million shares traded.